A venture capital fund based in the East Coast leads investments in high growth, mostly US-based digital health, SaaS, PaaS and technology-enabled service businesses. The firm has a flexible model to right-size equity investments with initial investments typically in the range of $1M to $10M. The firm is active in governance and seeks to remain involved through multiple financing rounds. The fund targets a 5-year investment window.

The fund’s investments are focused on a few key themes in businesses that improve the human condition and deliver value-based care. It seeks investments in B2B or B2B2C companies with proven business models and experienced teams pursuing end-market opportunities large enough to support creation of companies with $1B in enterprise value. Thematic areas of focus include personalized medicine, patient navigation, referral management, and enablement of payer-provider risk sharing.

The firm is open to working with management teams with various levels of experience. The fund does seek a board seat along with investment and prefers to be fairly involved with the management team and strategy of the company. The fund does not purchase secondary shares of a company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A specialized USA venture capital firm under a large Chinese holding company has headquarters in Shanghai, China and an additional virtual office in the USA. The firm is actively seeking investment opportunities from early-stage to pre-IPO rounds.  The average size of investment is around $5M. The firm has invested in 17 US & Canada companies since 2016.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm will also consider orphan drugs and digital health companies. The firm is open to all kinds of sectors. The firm is open to medical devices with all FDA regulatory pathways, including 510k and PMA.  The firm is open to medical devices and therapeutics in any stage of development. However, the firm will invest in private companies only.

The firm has no specific requests on the management team. The firm can act as the lead investor or co-investor depends on different cases, and the firm prefers to have a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm based in the USA has a newly established venture capital strategy, which has a specific focus in early-stage, pre-revenue biotech companies. The firm’s initial investment is usually around $500K, but the firm has invested as low as $250K and as high as $2-3M. At present, the firm is primarily looking for USA-based opportunities with a focus on the Midwest and East Coast regions.

The firm invests broadly across early-stage therapeutics, medical devices, and diagnostics. The firm is most interested in technologies with strong intellectual property. The firm is open to investing in all classes of medical devices including 510k and PMA. The firm works closely with a group of scientists who covers a wide range of expertise including cancer diagnostics, immunotherapy, diseases of the ear and eye, etc. The firm is not interested in healthcare analytics companies.

The firm is flexible and is open to working with all different kinds of management teams, though experience and a successful track record is a plus. The firm has both led and co-invested in financing rounds and seeks board representation most of the time.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices in the USA and Europe is currently investing from the firm’s newest $585 million venture fund. The firm is open to investment opportunities globally.

The firm is currently interested in novel concepts and platforms across the life sciences. The firm invests in therapeutics, devices and diagnostics, and has a lesser interest in technology-led companies in the healthcare IT space (the firm is not interested in service-based/SaaS healthcare IT businesses). The firm prefers early stage opportunities; in therapeutics, the firm focuses on pre-IND technologies.

While the firm invests across many areas, one focus at present is immunology assets that aim to treat infectious diseases (viral and bacterial), with a focus on immune priming or changing the immune system. Any immunological therapeutic modality is of interest, including vaccines. The firm is interested in reviewing immunology assets at any stage of development.

The firm only invests in privately held companies that have not previously raised a Series A round or a significant seed round. The firm is a highly hands-on, active investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2012 with $300M AUM is currently investing from its third fund. The firm focuses on early-stage investments from Seed to Series A, and initial size of investment can range from $500K to up to $3M. The firm reserves a significant part of the fund as follow-on investment. With the current fund, the firm seeks to invest in a total of 6-8 companies, with a preference for companies that are within proximity to their office in the Bay area.

The firm is interested in technologies that incorporate mobility and data. In terms of life sciences and healthcare, this includes digital health, AI and big data in discovery, precision medicine, etc. The firm has made several investments in digital health companies – examples include a mobile coaching app that promotes smarter decisions and better outcomes, a digital health platform for chronic disease management, etc.

The firm looks for driven management teams – relevant industry experience is a definite plus, but not an absolute requirement. The firm works closely with portfolio companies, providing companies with the needed resources and expertise to achieve scalability. The firm prefers to act as the lead investor, typically taking a board seat in such cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A single family office based in the USA with a team of particularly strong expertise in building and growing biotechnology and pharmaceutical companies invests broadly in healthcare and is open to companies of all stages. The size of investment can largely vary depending on the stage of the company. The firm has invested mainly in USA-based companies but is open to global opportunities.

The firm has a broad interest in healthcare and is most interested in private biotech companies, with a few investments in medical device companies as well. Within therapeutics, the firm’s sweet spot is from pre-clinical to late-stage II, with particular interest in assets with accelerated or de-risked regulatory pathways. The firm is interested in all indications, including oncology and immunotherapies. The firm also considers gene therapy as an area of high interest. In terms of medical devices, the firm is most interested in minimally invasive devices and is open to 510k and PMA regulatory pathways.

The firm seeks to work with experienced management teams with strong scientific expertise. Another important consideration is other investors that have participated in the financing. The firm invests in both public and private companies and will most likely seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in China has over $4 billion in total managed assets in the areas of healthcare, technology and internet, and clean tech. The firm has invested in more than 70 healthcare companies that span most sectors of life sciences from pharmaceuticals and medical devices to healthcare IT, diagnostics and select healthcare services.

The firm closed their healthcare fund in early 2018, focused on early-stage health care opportunities in the US with potential market opportunities in China. The firm has USA operations in both the West and East Coast. The firm intends to lead, co-lead, or co-invest in US-based private companies in biotech for therapeutics, medtech, and digital health technologies, with equity investments ranging from $5 to $15 million. The firm will not make public company investments.

The firm is open to many sectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is most interested in breakthrough products and technologies that address a large unmet need. The firm seeks investments in 510K devices and will invest in devices in the PMA pathway depending on stage, preferably clinical or later. In therapeutics, the firm is modality-agnostic but generally seeking opportunities that are past the pre-clinical stage. The firm is also interested in enabling technologies for drug discovery and development, and other healthcare-related technologies in the “digital-health” space.

The firm is seeking to invest in companies with novel ideas and technology and experienced and passionate management. Given the firm’s slogan of “inspiring people with the wisdom to succeed with diligence,” The firm’s team is “hands-on” and typically assumes a board seat after an investment. Investments in US companies are expected to have upside opportunities in China and can leverage the firm’s China network and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.